Overview

An Open-label, Phase 2 Study to Assess the Efficacy and Safety of Nemolizumab in Subjects With Systemic Sclerosis

Status:
Not yet recruiting

Trial end date:
2023-10-31

Target enrollment:

Participant gender:

Summary

To evaluate the efficacy of nemolizumab in systemic sclerosis patients. To evaluate also the safety and pharmacokinetics.

Phase:

Phase 2

Details

Lead Sponsor:

Maruho Co., Ltd.